Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone650-327-3270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$251.25 million
Profitability
Miscellaneous
Employees166
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Monday, February, 25th. The biotechnology company reported $0.18 EPS for the quarter, topping the Zacks' consensus estimate of $0.14 by $0.04. The biotechnology company had revenue of $66.80 million for the quarter, compared to the consensus estimate of $70.43 million. Corcept Therapeutics had a return on equity of 30.30% and a net margin of 29.97%. The firm's revenue was up 25.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 earnings per share. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What guidance has Corcept Therapeutics issued on next quarter's earnings?
Corcept Therapeutics updated its FY 2019 earnings guidance on Monday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $285-315 million.
What price target have analysts set for CORT?
3 analysts have issued 1 year price targets for Corcept Therapeutics' shares. Their forecasts range from $11.00 to $14.00. On average, they anticipate Corcept Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.
What is the consensus analysts' recommendation for Corcept Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corcept Therapeutics.
What are Wall Street analysts saying about Corcept Therapeutics stock?
Here are some recent quotes from research analysts about Corcept Therapeutics stock:
- 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug, Korlym. Notably, its efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential significantly. The company is also making attempts to develop its pipeline with its most advanced candidate relacorilant (CORT125134), currently under evaluation in a phase II study for Cushing's syndrome. The successful development of its pipeline candidates will further boost the company’s portfolio and lead to increased sales. However, Corcept’s share price movement shows that the stock has underperformed the industry year to date. Moreover, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future quarters." (4/5/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are Neutral on CORT with a 12-month price target of $17 based on value from Korlym. Yesterday, after market close, Corcept reported 3Q18 revenues of $64.4M & cash of $196.7M. Our model projects current cash & Korlym profits to fund operations through the P3 study of Relacorilant in Cushing’s as well as signal-seeking studies underway with several earlier candidates. 3Q call centered on sustainability of Korlym sales growth and Rela’s P3. Korlym sales grew 51% in 3Q18 compared to 3Q17. We believe that this growth is a result of the company’s effective outreach and education efforts to physicians that has yet to peak as there are prescribers it has yet to engage." (11/2/2018)
Has Corcept Therapeutics been receiving favorable news coverage?
News headlines about CORT stock have been trending very positive this week, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a news impact score of 3.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting Corcept Therapeutics?
Corcept Therapeutics saw a increase in short interest in March. As of March 29th, there was short interest totalling 25,204,409 shares, an increase of 0.7% from the March 15th total of 25,028,508 shares. Based on an average trading volume of 759,764 shares, the days-to-cover ratio is currently 33.2 days. Approximately 24.4% of the company's stock are sold short. View Corcept Therapeutics' Current Options Chain.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include Alkermes (ALKS), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Evotec (EVTCY), Amneal Pharmaceuticals (AMRX), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE) and Agios Pharmaceuticals (AGIO).
What other stocks do shareholders of Corcept Therapeutics own?
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO, & Director (Age 62)
- Mr. Gary Charles Robb, CFO & Sec. (Age 56)
- Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
- Donald E. Laferle, Sr. VP
Who are Corcept Therapeutics' major shareholders?
Corcept Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (7.30%), Peregrine Capital Management LLC (0.42%), Tealwood Asset Management Inc. (0.13%) and Valeo Financial Advisors LLC (0.02%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.
Which major investors are selling Corcept Therapeutics stock?
CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Peregrine Capital Management LLC. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.
Which major investors are buying Corcept Therapeutics stock?
CORT stock was acquired by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc. and Valeo Financial Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $11.96.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $1.37 billion and generates $251.25 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.60 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.
What is Corcept Therapeutics' official website?
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
